Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Policy & Regulation
Trends & Finance
Moderate Complexity Test
Immunovia nabs CMS preliminary payment determination
By
LabPulse.com staff writers
The CMS preliminary payment determination implied a test price of $897.
September 26, 2022
Bionano launches first optical genome mapping-based LDT
By
LabPulse.com staff writers
The firm also launched Bionano Laboratories' first OGM-based laboratory developed test, for facioscapulohumeral muscular dystrophy (FSHD), the second-leading cause of muscular dystrophy and an important marker in the evaluation of muscular disorders, Bionano Genomics said.
September 22, 2022
Allelica launches polygenic risk score analysis as LDT
By
LabPulse.com staff writers
The firm said its tests are made possible through a partnership with Clinical Enterprise, a CLIA-certified, CAP-accredited laboratory located in Framingham, MA.
September 20, 2022
FDA grants EUA for Qorvo COVID-19 antigen test
By
LabPulse.com staff writers
The test is authorized for the detection of nucleocapsid viral antigens from COVID-19 in nasal swab specimens taken within six days of symptom onset from those who are suspected of having COVID-19.
August 3, 2022
North American Diagnostics recalls COVID-19 rapid tests
By
LabPulse.com staff writers
"North American Diagnostics did not provide the FDA with adequate validation data to show that the test's performance is accurate," the FDA wrote in the recall announcement. "This means there is a risk of potential false negative, false positive, or misinterpretation of results."
July 31, 2022
Exact Sciences supports CMS screening policy changes
By
LabPulse.com staff writers
The CMS Calendar Year 2023 Physician Fee Schedule proposal considers follow-up colonoscopy to an at-home test as a preventative service. The rule would eliminate all costs to Medicare patients for a follow-up colonoscopy following a positive at-home colorectal cancer screening test.
July 10, 2022
Helio Genomics obtains CPT code for liver cancer test
By
LabPulse.com staff writers
When it takes effect on October 1, the new CPT PLA code will provide a reimbursement pathway to enable increased access to HelioLiver, according to the vendors.
July 4, 2022
AACC lobbies against greater regulation of lab-developed tests
By
Erik L. Ridley
The Verifying Accurate Leading-edge IVCT Development (VALID) Act would limit the availability of laboratory-developed tests, decreasing patient access to these diagnostic tools, the AACC said. Often created when there is no FDA-approved commercial test available, these tests are frequently used to diagnose rare conditions -- such as genetic abnormalities in children -- or to respond to emerging health threats such as COVID-19, according to the association.
May 24, 2022
CAP weighs in on U.S. Senate's FDA user fee authorization bill
By
LabPulse.com staff writers
The bill would mandate greater regulatory oversight of laboratory-developed tests (LDTs) and includes sections of the Verifying Accurate Leading-edge IVCT Development (VALID) Act, the CAP said.
May 17, 2022
Qiagen's new HSV assay cleared in Europe
By
LabPulse.com staff writers
With this latest regulatory clearance, Qiagen is now offering 15 CE-IVD assays for use on NeuMoDx 96 and 288 systems, in addition to the capability to process laboratory-developed tests (LDTs), the company said.
May 5, 2022
AACC criticizes FDA over warning on prenatal genetic tests
By
Will Morton
NIPTs can determine the risk of a fetus having certain genetic abnormalities, which could result in a child being born with a serious health condition. However, since they are not diagnostic tests, they cannot confirm or rule out a suspected genetic abnormality, the FDA said.
April 21, 2022
Immunovia applies to AMA for PLA code
By
LabPulse.com staff writers
The company has touted the results of a study showing that the test detected stage I/II pancreatic ductal adenocarcinoma with 99% specificity and 89% sensitivity.
April 17, 2022
Page 1 of 8
Next Page